Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Tunlametinib is a MEK1 inhibitor (IC50 = 1.9 nM).1 It is selective for MEK1 over a panel of other kinases at 10 µM. Tunlametinib selectively reduces proliferation in a panel of cancer cell lines expressing mutant K-Ras or B-RAF (IC50s = 0.67-59.89 nM) over H1975 cells expressing wild-type K-Ras and B-RAF (IC50 = >1,000 nM). It also inhibits the phosphorylation of ERK in A375 melanoma cells (IC50 = 1.16 nM). In vivo, tunlametinib (1, 3, and 9 mg/kg) inhibits intratumoral ERK phosphorylation in an A375 mouse xenograft model and reduces tumor growth in the same model when administered at doses of 3 and 9 mg/kg.
WARNING This product is not for human or veterinary use.
1. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Front. Pharmacol. 14, 1271268 (2023).